Table 3.
Hemodynamic parameters during prone positioning session
| Variables | T1 | T2 | T3 | T4 |
|---|---|---|---|---|
| HR (min−1) | 98 ± 23 | 99 ± 20a | 96 ± 20 | 95 ± 21 |
| MAP (mmHg) | 76 ± 10 | 79 ± 12c | 77 ± 12 | 78 ± 14 |
| CVP (cm H2O) | 13 ± 5 | 14 ± 5c | 13 ± 5 | 14 ± 5 |
| CI (L min m−2) | 3.5 ± 1.3a | 3.4 ± 1.2a | 3.4 ± 1.1a | 3.2 ± 1.1 |
| GEF (%) | 21 ± 7 | 20 ± 7c | 21 ± 8 | 21 ± 7 |
| EVLWI (mL kg−1 PBW) | 13.8 ± 4.4 | 14.2 ± 4.7a | 13.7 ± 4.7 | 13.1 ± 4.0 |
| PVPI | 2.6 ± 1.0b | 2.5 ± 0.9 | 2.4 ± 0.9 | 2.5 ± 0.9 |
| GEDVI (mL m−2) | 719 ± 193 | 738 ± 185a,c | 757 ± 209a,c | 714 ± 200 |
| CFI (min−1) | 5.0 ± 1.9 | 4.8 ± 1.8c | 4.8 ± 1.8c | 4.7 ± 1.8c |
| PTV (mL) | 1163 ± 362a | 1189 ± 359a | 1173 ± 354a | 1116 ± 327 |
| ITTV (mL) | 2539 ± 653 | 2602 ± 638a,c | 2619 ± 664a,c | 2482 ± 655 |
| DO2 (mL min m−2) | 416 ± 145 | NA | 414 ± 139 | 387 ± 126b,c |
| Vasopressor dose* (µg kg min−1) | 0.92 ± 1.66 | 0.92 ± 2.04 | 0.84 ± 1.67c | 0.88 ± 1.76c |
| Dobutamine dose** (µg kg min−1) | 2.6 ± 6.0 | 2.6 ± 5.8 | 2.8 ± 6.1 | 3.0 ± 6.2 |
| Volume of fluid challenge since preceding time point*** (mL) | NA | 158 ± 519 | 224 ± 566 | 123 ± 340 |
Values are mean ± standard deviation. All statistical tests are performed after adjustment for volume of fluid challenges since preceding time point, vasopressor and dobutamine dose unless specifically stated
CI, cardiac index; CFI, cardiac function index; CVP, central venous pressure; DO2, oxygen delivery; EVLWI, extravascular lung water index; GEDVI, global end-diastolic volume index; GEF, global ejection fraction; HR, heart rate; ITTV, intrathoracic thermal volume; MAP, mean arterial pressure; NA, not available; PBW, predicted body weight; PTV, pulmonary thermal volume; PVPI, pulmonary vascular permeability index; T1, before prone position, T2, beginning of prone position session; T3, end of prone position session; T4, after prone position session
ap < 0.05 versus T4; b p < 0.05 versus T3; c p < 0.05 versus T1
* Adjustment for volume of fluid challenges since preceding time point and dobutamine dose only; ** adjustment for volume of fluid challenges since preceding time point and vasopressor dose only; *** not tested for statistical significance